No Data
D. Boral Capital Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Maintains Target Price $10
Can-Fite BioPharma to Present Data on Namodenoson at 2025 ASCO Gastrointestinal Cancers Symposium
Express News | Can-Fite To Present Data At The 2025 Asco Gastrointestinal Cancers Symposium; Enrolls Patients For Its Pivotal Phase III Dvanced Liver Cancer Study
Express News | Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"
Bears Are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital
